研究表明,药物组合Belzutifan和Cabozantinib可以为高级肾癌患者带来新的希望。 Study shows drug combo belzutifan and cabozantinib could offer new hope for advanced kidney cancer patients.

Dana-Farber癌症研究所最近进行的一项研究发现,将Belzutifan和Cabozantinib这两种药物结合起来,在治疗高级肾癌方面取得了有希望的成果。 A recent study by the Dana-Farber Cancer Institute found that a combination of drugs, belzutifan and cabozantinib, showed promising results in treating advanced kidney cancer. 对于未经治疗的病人,70%的病人的治疗效果显著,有些病人完全恢复了病情。 For untreated patients, 70% saw a significant response, with some experiencing complete remission. 治疗具有可管理的副作用。 The treatment had manageable side effects. 这种新颖的结合可能是一种新的一线治疗选择,为肾癌患者带来更好的结果带来希望。 This novel combination could be a new first-line therapy option, offering hope for better outcomes in kidney cancer patients.